Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers

<p>Abstract</p> <p>Background</p> <p>Genomic gains and losses are a result of genomic instability in many types of cancers. <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers are associated with increased amounts of chromosomal aberrations...

Full description

Bibliographic Details
Main Authors: Holstege Henne, van Beers Erik, Velds Arno, Liu Xiaoling, Joosse Simon A, Klarenbeek Sjoerd, Schut Eva, Kerkhoven Ron, Klijn Christiaan N, Wessels Lodewyk FA, Nederlof Petra M, Jonkers Jos
Format: Article
Language:English
Published: BMC 2010-08-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/455
id doaj-949f7d272759472b840fe8c6dba209fb
record_format Article
spelling doaj-949f7d272759472b840fe8c6dba209fb2020-11-25T00:05:20ZengBMCBMC Cancer1471-24072010-08-0110145510.1186/1471-2407-10-455Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancersHolstege Hennevan Beers ErikVelds ArnoLiu XiaolingJoosse Simon AKlarenbeek SjoerdSchut EvaKerkhoven RonKlijn Christiaan NWessels Lodewyk FANederlof Petra MJonkers Jos<p>Abstract</p> <p>Background</p> <p>Genomic gains and losses are a result of genomic instability in many types of cancers. <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers are associated with increased amounts of chromosomal aberrations, presumably due their functions in genome repair. Some of these genomic aberrations may harbor genes whose absence or overexpression may give rise to cellular growth advantage. So far, it has not been easy to identify the driver genes underlying gains and losses. A powerful approach to identify these driver genes could be a cross-species comparison of array comparative genomic hybridization (aCGH) data from cognate mouse and human tumors. Orthologous regions of mouse and human tumors that are commonly gained or lost might represent essential genomic regions selected for gain or loss during tumor development.</p> <p>Methods</p> <p>To identify genomic regions that are associated with <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers we compared aCGH data from 130 mouse <it>Brca1</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ</it></sup>, <it>Brca2</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ </it></sup>and <it>p53</it><sup><it>Δ/Δ </it></sup>mammary tumor groups with 103 human <it>BRCA1-</it>mutated, <it>BRCA2-</it>mutated and non-hereditary breast cancers.</p> <p>Results</p> <p>Our genome-wide cross-species analysis yielded a complete collection of loci and genes that are commonly gained or lost in mouse and human breast cancer. Principal common CNAs were the well known <it>MYC</it>-associated gain and <it>RB1/INTS6</it>-associated loss that occurred in all mouse and human tumor groups, and the <it>AURKA</it>-associated gain occurred in BRCA2-related tumors from both species. However, there were also important differences between tumor profiles of both species, such as the prominent gain on chromosome 10 in mouse <it>Brca2</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ </it></sup>tumors and the PIK3CA associated 3q gain in human <it>BRCA1-</it>mutated tumors, which occurred in tumors from one species but not in tumors from the other species. This disparity in recurrent aberrations in mouse and human tumors might be due to differences in tumor cell type or genomic organization between both species.</p> <p>Conclusions</p> <p>The selection of the oncogenome during mouse and human breast tumor development is markedly different, apart from the MYC gain and RB1-associated loss. These differences should be kept in mind when using mouse models for preclinical studies.</p> http://www.biomedcentral.com/1471-2407/10/455
collection DOAJ
language English
format Article
sources DOAJ
author Holstege Henne
van Beers Erik
Velds Arno
Liu Xiaoling
Joosse Simon A
Klarenbeek Sjoerd
Schut Eva
Kerkhoven Ron
Klijn Christiaan N
Wessels Lodewyk FA
Nederlof Petra M
Jonkers Jos
spellingShingle Holstege Henne
van Beers Erik
Velds Arno
Liu Xiaoling
Joosse Simon A
Klarenbeek Sjoerd
Schut Eva
Kerkhoven Ron
Klijn Christiaan N
Wessels Lodewyk FA
Nederlof Petra M
Jonkers Jos
Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
BMC Cancer
author_facet Holstege Henne
van Beers Erik
Velds Arno
Liu Xiaoling
Joosse Simon A
Klarenbeek Sjoerd
Schut Eva
Kerkhoven Ron
Klijn Christiaan N
Wessels Lodewyk FA
Nederlof Petra M
Jonkers Jos
author_sort Holstege Henne
title Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
title_short Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
title_full Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
title_fullStr Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
title_full_unstemmed Cross-species comparison of aCGH data from mouse and human <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers
title_sort cross-species comparison of acgh data from mouse and human <it>brca1</it>- and <it>brca2</it>-mutated breast cancers
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2010-08-01
description <p>Abstract</p> <p>Background</p> <p>Genomic gains and losses are a result of genomic instability in many types of cancers. <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers are associated with increased amounts of chromosomal aberrations, presumably due their functions in genome repair. Some of these genomic aberrations may harbor genes whose absence or overexpression may give rise to cellular growth advantage. So far, it has not been easy to identify the driver genes underlying gains and losses. A powerful approach to identify these driver genes could be a cross-species comparison of array comparative genomic hybridization (aCGH) data from cognate mouse and human tumors. Orthologous regions of mouse and human tumors that are commonly gained or lost might represent essential genomic regions selected for gain or loss during tumor development.</p> <p>Methods</p> <p>To identify genomic regions that are associated with <it>BRCA1</it>- and <it>BRCA2</it>-mutated breast cancers we compared aCGH data from 130 mouse <it>Brca1</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ</it></sup>, <it>Brca2</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ </it></sup>and <it>p53</it><sup><it>Δ/Δ </it></sup>mammary tumor groups with 103 human <it>BRCA1-</it>mutated, <it>BRCA2-</it>mutated and non-hereditary breast cancers.</p> <p>Results</p> <p>Our genome-wide cross-species analysis yielded a complete collection of loci and genes that are commonly gained or lost in mouse and human breast cancer. Principal common CNAs were the well known <it>MYC</it>-associated gain and <it>RB1/INTS6</it>-associated loss that occurred in all mouse and human tumor groups, and the <it>AURKA</it>-associated gain occurred in BRCA2-related tumors from both species. However, there were also important differences between tumor profiles of both species, such as the prominent gain on chromosome 10 in mouse <it>Brca2</it><sup><it>Δ/Δ</it></sup><it>;p53</it><sup><it>Δ/Δ </it></sup>tumors and the PIK3CA associated 3q gain in human <it>BRCA1-</it>mutated tumors, which occurred in tumors from one species but not in tumors from the other species. This disparity in recurrent aberrations in mouse and human tumors might be due to differences in tumor cell type or genomic organization between both species.</p> <p>Conclusions</p> <p>The selection of the oncogenome during mouse and human breast tumor development is markedly different, apart from the MYC gain and RB1-associated loss. These differences should be kept in mind when using mouse models for preclinical studies.</p>
url http://www.biomedcentral.com/1471-2407/10/455
work_keys_str_mv AT holstegehenne crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT vanbeerserik crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT veldsarno crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT liuxiaoling crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT joossesimona crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT klarenbeeksjoerd crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT schuteva crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT kerkhovenron crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT klijnchristiaann crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT wesselslodewykfa crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT nederlofpetram crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
AT jonkersjos crossspeciescomparisonofacghdatafrommouseandhumanitbrca1itanditbrca2itmutatedbreastcancers
_version_ 1725425621396357120